Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel

Institut Curie30 enrolled

Overview

The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.

In this study, there is no experimental treatment, or experimental care.

Study Type

INTERVENTIONAL

Allocation

Masking

NONE

Enrollment

Conditions

Tumors

Interventions

blood samplingOTHER

Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule. * Patient with bitherapy are eligible only if the taxane is the first infusion. * All type of tumor. * Age\>18 years old. * Signed written informed consent. Exclusion Criteria: * Patient under 18. * Patient with bitherapy, if docetaxel or paclitaxel is not administered first. * Patient deprived of liberty.

Locations (1)

Institut Curie

Paris, France

Outcomes

Primary Outcomes

Evaluation of plasma alcohol

Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)

Time frame: One year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.